NXL vs. DRUG

Last updated Jun 3, 2026

NXL (Nexalin Technology Inc.) and DRUG (Bright Minds Biosciences Inc) are both stocks. Both are in the Healthcare sector — NXL in Medical Devices, DRUG in Biotechnology. Over the past 3 years, NXL returned -14.82%/yr vs 197.03%/yr for DRUG. At a 0.06 correlation, their price movements are largely independent.

Performance

NXL vs. DRUG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nexalin Technology Inc. (NXL) and Bright Minds Biosciences Inc (DRUG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NXL achieves a -1.43% return, which is significantly higher than DRUG's -1.61% return.

NXL

• 1D: -4.60%
• 1M: 44.62%
• YTD: -1.43%
• 6M: -43.30%
• 1Y: -54.92%
• 3Y*: -14.82%
• 5Y*: —
• 10Y*: —

DRUG

• 1D: -5.23%
• 1M: -11.71%
• YTD: -1.61%
• 6M: 9.16%
• 1Y: 171.12%
• 3Y*: 197.03%
• 5Y*: 27.54%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NXL vs. DRUG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NXL Nexalin Technology Inc.	-1.43%	-79.78%	581.82%	-45.95%	-66.71%
DRUG Bright Minds Biosciences Inc	-1.61%	116.66%	2,418.88%	-61.35%	-50.67%

Correlation

The correlation between NXL and DRUG is 0.10, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (All Time) Calculated using the full available price history since Sep 19, 2022	0.06

Fundamentals

Market Cap NXL : $10.90M DRUG : $736.31M
EPS NXL : -$0.46 DRUG : -$3.48
PB Ratio NXL : 3.78 DRUG : 2.39
Total Revenue (TTM) NXL : $275.58K DRUG : $0.00
Gross Profit (TTM) NXL : -$950.31K DRUG : -$20.13K
EBITDA (TTM) NXL : -$8.37M DRUG : -$31.36M

Return for Risk

NXL vs. DRUG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NXL

NXL Risk / Return Rank: 25
NXL Sharpe Ratio Rank: 24
NXL Sortino Ratio Rank: 31
NXL Omega Ratio Rank: 31
NXL Calmar Ratio Rank: 17
NXL Martin Ratio Rank: 20

DRUG

DRUG Risk / Return Rank: 90
DRUG Sharpe Ratio Rank: 91
DRUG Sortino Ratio Rank: 88
DRUG Omega Ratio Rank: 83
DRUG Calmar Ratio Rank: 94
DRUG Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NXL vs. DRUG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nexalin Technology Inc. (NXL) and Bright Minds Biosciences Inc (DRUG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NXL	DRUG	Difference
Sharpe ratio Return per unit of total volatility	-0.38	2.39	-2.77
Sortino ratio Return per unit of downside risk	0.07	3.06	-2.99
Omega ratio Gain probability vs. loss probability	1.01	1.34	-0.34
Calmar ratio Return relative to maximum drawdown	-0.65	6.83	-7.48
Martin ratio Return relative to average drawdown	-0.99	15.58	-16.57
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NXL vs. DRUG - Sharpe Ratio Comparison

The current NXL Sharpe Ratio is -0.38, which is lower than the DRUG Sharpe Ratio of 2.39. The chart below compares the historical Sharpe Ratios of NXL and DRUG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NXL	DRUG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.38	2.39	-2.77
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	0.03	-0.23

Drawdowns

NXL vs. DRUG - Drawdown Comparison

The maximum NXL drawdown since its inception was -92.64%, smaller than the maximum DRUG drawdown of -97.68%. Use the drawdown chart below to compare losses from any high point for NXL and DRUG.

Drawdown Indicators

	NXL	DRUG	Difference
Max Drawdown Largest peak-to-trough decline	-92.64%	-97.68%	+5.04%
Max Drawdown (1Y) Largest decline over 1 year	-82.74%	-28.69%	-54.05%
Max Drawdown (3Y) Largest decline over 3 years	-92.64%	-76.98%	-15.66%
Max Drawdown (5Y) Largest decline over 5 years	—	-97.68%	—
Current Drawdown Current decline from peak	-87.39%	-20.01%	-67.38%
Average Drawdown Average peak-to-trough decline	-64.28%	-59.06%	-5.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	54.37%	12.57%	+41.80%

Volatility

NXL vs. DRUG - Volatility Comparison

Nexalin Technology Inc. (NXL) has a higher volatility of 36.68% compared to Bright Minds Biosciences Inc (DRUG) at 19.68%. This indicates that NXL's price experiences larger fluctuations and is considered to be riskier than DRUG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NXL	DRUG	Difference
Volatility (1M) Calculated over the trailing 1-month period	36.68%	19.68%	+17.00%
Volatility (6M) Calculated over the trailing 6-month period	74.42%	46.72%	+27.70%
Volatility (1Y) Calculated over the trailing 1-year period	145.07%	72.56%	+72.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	166.22%	662.71%	-496.49%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	166.22%	650.04%	-483.82%

Dividends

NXL vs. DRUG - Dividend Comparison

Neither NXL nor DRUG has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NXL and DRUG in my portfolio?

NXL and DRUG have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NXL or DRUG?

NXL has higher volatility (36.68%) compared to DRUG (19.68%). In terms of maximum drawdown, NXL dropped -92.64% vs DRUG's -97.68%.

Which has better risk-adjusted returns?

DRUG currently has the higher Sharpe Ratio (2.39 vs -0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.